{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T09:13:46Z","timestamp":1792919626084,"version":"4.5.0"},"reference-count":58,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Hereditary thrombotic thrombocytopenic purpura (hTTP), also known as Upshaw\u2013Schulman syndrome, is a rare genetic disorder caused by mutations in the ADAMTS13 gene that leads to decreased or absent production of the plasma von Willebrand factor (VWF)-cleaving metalloprotease ADAMTS13. The result is circulating ultra-large multimers of VWF that can cause microthrombi, intravascular occlusion and organ damage, especially at times of turbulent circulation. Patients with hTTP may have many overt or clinically silent manifestations, and a high index of suspicion is required for diagnosis. For the treatment of hTTP, the goal is simply replacement of ADAMTS13. The primary treatment is prophylaxis with plasma infusions or plasma-derived factor VIII products, providing sufficient ADAMTS13 to prevent acute episodes. When acute episodes occur, prophylaxis is intensified. Recombinant ADAMTS13, which is near to approval, will immediately be the most effective and also the most convenient treatment. In this review, we discuss the possible clinical manifestations of this rare disease and the relevant differential diagnoses in different age groups. An extensive discussion on prophylaxis and treatment strategies is also presented. Unique real patient cases have been added to highlight critical aspects of hTTP manifestations, diagnosis and treatment.<\/jats:p>","DOI":"10.3390\/genes14101956","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T09:55:06Z","timestamp":1697622906000},"page":"1956","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Hereditary Thrombotic Thrombocytopenic Purpura"],"prefix":"10.3390","volume":"14","author":[{"given":"Sanober","family":"Nusrat","sequence":"first","affiliation":[{"name":"Hematology-Oncology Section, Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kisha","family":"Beg","sequence":"additional","affiliation":[{"name":"Jimmy Everest Section of Pediatric Hematology-Oncology, Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman","family":"Khan","sequence":"additional","affiliation":[{"name":"Jimmy Everest Section of Pediatric Hematology-Oncology, Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9882-4291","authenticated-orcid":false,"given":"Arpan","family":"Sinha","sequence":"additional","affiliation":[{"name":"Jimmy Everest Section of Pediatric Hematology-Oncology, Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"George","sequence":"additional","affiliation":[{"name":"Hematology-Oncology Section, Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMra1813013","article-title":"Hereditary Thrombotic Thrombocytopenic Purpura","volume":"381","author":"George","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1111\/jth.15006","article-title":"ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/35097008","article-title":"Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura","volume":"413","author":"Levy","year":"2001","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"41059","DOI":"10.1074\/jbc.C100515200","article-title":"Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura","volume":"276","author":"Zheng","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/jth.13898","article-title":"ADAMTS-13 and von Willebrand factor: A dynamic duo","volume":"16","author":"South","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/blood-2014-06-528406","article-title":"von Willebrand factor biosynthesis, secretion, and clearance: Connecting the far ends","volume":"125","author":"Lenting","year":"2015","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7858","DOI":"10.1038\/ncomms8858","article-title":"Flow-driven assembly of VWF fibres and webs in in vitro microvessels","volume":"6","author":"Zheng","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.3324\/haematol.2019.216796","article-title":"The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: Key findings at enrollment until 2017","volume":"104","author":"Taleghani","year":"2019","journal-title":"Haematologica"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/jth.13956","article-title":"Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome","volume":"16","author":"Heeb","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/humu.21143","article-title":"ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura","volume":"31","author":"Lotta","year":"2010","journal-title":"Hum. Mutat."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2012-01-403113","article-title":"Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura","volume":"120","author":"Lotta","year":"2012","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1538-7836.2011.04341.x","article-title":"Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan","volume":"9","author":"Fujimura","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/jth.13186","article-title":"High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: From clinical observation to evidence","volume":"14","author":"Waage","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1182\/bloodadvances.2019000601","article-title":"Patent ductus arteriosus generates neonatal hemolytic jaundice with thrombocytopenia in Upshaw-Schulman syndrome","volume":"3","author":"Fujimura","year":"2019","journal-title":"Blood Adv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e12820","DOI":"10.1002\/rth2.12820","article-title":"Early indicators of neonatal-onset hereditary thrombotic thrombocytopenia purpura","volume":"6","author":"Liu","year":"2022","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e12840","DOI":"10.1002\/rth2.12840","article-title":"Hereditary thrombotic thrombocytopenic purpura: The risk for death at birth","volume":"6","author":"George","year":"2022","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/bloodadvances.2021005760","article-title":"Morbidities and mortality in patients with hereditary thrombotic thrombocytopenic purpura","volume":"6","author":"Borogovac","year":"2022","journal-title":"Blood Adv."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMc2210781","article-title":"Recombinant ADAMTS13 in Severe Neonatal Thrombotic Thrombocytopenic Purpura","volume":"387","author":"Stubbs","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1182\/asheducation-2015.1.146","article-title":"Hemolytic disease of the fetus and newborn: Managing the mother, fetus, and newborn","volume":"2015","author":"Delaney","year":"2015","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Gabbay, J.M., Agneta, E.M., Turkington, S., Bajaj, B.M., Sinha, B., and Geha, T. (2023). Rates of phototherapy among ABO-incompatible newborns with a negative direct antiglobulin test. J. Perinatol., 1\u20136.","DOI":"10.1038\/s41372-023-01650-3"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1179\/2046905512Y.0000000002","article-title":"Morbidity of ABO haemolytic disease in the newborn","volume":"32","author":"Bhat","year":"2012","journal-title":"Paediatr. Int. Child. Health."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e28949","DOI":"10.1002\/pbc.28949","article-title":"Recognizing and managing hereditary and acquired thrombotic thrombocytopenic purpura in infants and children","volume":"68","author":"Siddiqui","year":"2021","journal-title":"Pediatr. Blood Cancer."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood-2018-11-884700","article-title":"Characterization and treatment of congenital thrombotic thrombocytopenic purpura","volume":"133","author":"Alwan","year":"2019","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1182\/bloodadvances.2019000959","article-title":"Stroke and myocardial infarction in hereditary thrombotic thrombocytopenic purpura: Similarities to sickle cell anemia","volume":"3","author":"Borogovac","year":"2019","journal-title":"Blood Adv."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/bjh.17126","article-title":"Cerebral MRI findings predict the risk of cognitive impairment in thrombotic thrombocytopenic purpura","volume":"191","author":"Alwan","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.2022016044","article-title":"Prevalence of neuropsychiatric symptoms and stroke in patients with hereditary thrombotic thrombocytopenic purpura","volume":"140","author":"Borogovac","year":"2022","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1182\/asheducation-2018.1.548","article-title":"TTP: Long-term outcomes following recovery","volume":"2018","author":"George","year":"2018","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/SMJ.0b013e318046583f","article-title":"Overlapping features of thrombotic thrombocytopenic purpura and systemic lupus erythematosus","volume":"100","author":"George","year":"2007","journal-title":"South. Med. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"E172","DOI":"10.1002\/ajh.25466","article-title":"Additional autoimmune disorders in patients with acquired autoimmune thrombotic thrombocytopenic purpura","volume":"94","author":"Hassan","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e1598","DOI":"10.1097\/MD.0000000000001598","article-title":"Risk Factors for Autoimmune Diseases Development After Thrombotic Thrombocytopenic Purpura","volume":"94","author":"Roriz","year":"2015","journal-title":"Medicine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1182\/blood.2020009801","article-title":"Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura","volume":"137","author":"Tarasco","year":"2021","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"E316","DOI":"10.1002\/ajh.25964","article-title":"Frequency and severity of pregnancy complications in women with hereditary thrombotic thrombocytopenic purpura","volume":"95","author":"Kasht","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/apm.12833","article-title":"Maternal vascular malperfusion of the placental bed","volume":"126","author":"Ernst","year":"2018","journal-title":"APMIS"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Soffer, M.D., Bendapudi, P.K., Roberts, D.J., Edelson, P.K., Kuter, D.J., Ecker, J.L., Bryant, A., and Goldfarb, I.T. (2020). Congenital thrombotic thrombocytopenic purpura (TTP) with placental abruption despite maternal improvement: A case report. BMC Pregnancy Childbirth, 20.","DOI":"10.1186\/s12884-020-03051-2"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1002\/ajh.26328","article-title":"Severe thrombocytopenia and microangiopathic hemolytic anemia in pregnancy: A guide for the consulting hematologist","volume":"96","author":"Reese","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1056\/NEJMoa2211113","article-title":"Recombinant ADAMTS13 for Hereditary Thrombotic Thrombocytopenic Purpura","volume":"387","author":"Asmis","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1182\/blood-2015-05-643338","article-title":"Low ADAMTS13 activity is associated with an increased risk of ischemic stroke","volume":"126","author":"Sonneveld","year":"2015","journal-title":"Blood"},{"key":"ref_39","first-page":"325","article-title":"Silent cerebral infarction during immune TTP remission: Prevalence, predictors, and impact on cognition","volume":"142","author":"Chaturvedi","year":"2023","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2017-06-788026","article-title":"Recombinant ADAMTS-13: First-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura","volume":"130","author":"Scully","year":"2017","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"E304","DOI":"10.1002\/ajh.26603","article-title":"Aspirin prophylaxis for hereditary and acquired thrombotic thrombocytopenic purpura?","volume":"97","author":"Shao","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/jth.14345","article-title":"Pharmacokinetics of plasma infusion in congenital thrombotic thrombocytopenic purpura","volume":"17","author":"Taylor","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/MPH.0b013e3182755c38","article-title":"Successful treatment of congenital TTP with a novel approach using plasma-derived factor VIII","volume":"35","author":"Naik","year":"2013","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ajh.23527","article-title":"ADAMTS13 content in plasma-derived factor VIII\/von Willebrand factor concentrates","volume":"88","author":"Peyvandi","year":"2013","journal-title":"Am. J. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/rth2.12225","article-title":"Illustrated State-of-the-Art Capsules of the ISTH 2019 Congress in Melbourne, Australia","volume":"3","author":"Ward","year":"2019","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Aledort, L.M., Boggio, L., Davis, J.A., Gauger, C., Kobrinsky, N.L., Rajasekhar, A., Shapiro, R., Torres, M., and Ulsh, P.J. (2015). Congenital Thrombotic Thrombocytopenia Purpura\u2014Safer Treatment with Plasma-Derived Viral-Attenuated Clotting Factor. Blood, 126.","DOI":"10.1182\/blood.V126.23.3459.3459"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1182\/blood-2022-162506","article-title":"Long-Term Follow-up of Patients with Congenital Thrombotic Thrombocytopenia Purpura Receiving Plasma-Derived Factor VIII Containing (Koate\u00ae)","volume":"140","author":"Boggio","year":"2022","journal-title":"Blood"},{"key":"ref_49","unstructured":"ISTH (2023). MS Phase 3 prospective, randomized, controlled, open-label, multicenter, crossover study of recombinant ADAMTS13 in patients with congenital thrombotic thrombocytopenic purpura, ISTH."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"E420","DOI":"10.1002\/ajh.26693","article-title":"Caplacizumab for congenital thrombotic thrombocytopenic purpura","volume":"97","author":"Boothby","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/jcph.1991","article-title":"Caplacizumab Model-Based Dosing Recommendations in Pediatric Patients with Acquired Thrombotic Thrombocytopenic Purpura","volume":"62","author":"Bergstrand","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.2020007599","article-title":"Real-world experience with caplacizumab in the management of acute TTP","volume":"137","author":"Dutt","year":"2021","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/gt.2009.98","article-title":"Adenoviral-mediated gene transfer restores plasma ADAMTS13 antigen and activity in ADAMTS13 knockout mice","volume":"16","author":"Trionfini","year":"2009","journal-title":"Gene Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/mt.2008.223","article-title":"Correction of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genes","volume":"17","author":"Niiya","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1182\/blood-2013-02-486779","article-title":"AAV-mediated expression of an ADAMTS13 variant prevents shigatoxin-induced thrombotic thrombocytopenic purpura","volume":"121","author":"Jin","year":"2013","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector\u2013mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","article-title":"Safety and efficacy of gene transfer for Leber\u2019s congenital amaurosis","volume":"358","author":"Maguire","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1182\/blood.2021012896","article-title":"Deletion of platelet CLEC-2 decreases GPIb\u03b1-mediated integrin \u03b1IIb\u03b23 activation and decreases thrombosis in TTP","volume":"139","author":"Shao","year":"2022","journal-title":"Blood"}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/14\/10\/1956\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:09:00Z","timestamp":1760130540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/14\/10\/1956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,18]]},"references-count":58,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["genes14101956"],"URL":"https:\/\/doi.org\/10.3390\/genes14101956","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,18]]}}}